Pulse Biosciences Inc Stock Price, News & Analysis

Pulse Biosciences (NASDAQ: PLSE) announced its nsPFA™ System showcased in a poster presentation at the 28th Annual International AF Symposium in Boston from February 2-4. The technology integrates with CardioNXT’s iMap system, demonstrating effective cardiac ablation and mapping capabilities. The preclinical studies suggest that the nsPFA System may improve patient outcomes by combining advanced technologies for treating atrial fibrillation. CEO Kevin Danahy indicated optimism about early results, emphasizing the potential of the new catheter system.

Pulse Biosciences (PLSE) released its third-quarter financial results for 2022, reporting no revenue and a GAAP net loss of $18.0 million, up from a loss of $14.3 million in Q3 2021. Total expenses rose to $18.0 million, including a $7.2 million inventory reserve for dermatology. Cash reserves improved to $69.2 million, compared to $14.8 million in Q2 2022. The company is focusing on cardiac ablation for atrial fibrillation and anticipates a quarterly cash burn of approximately $8 million starting Q1 2023. A $65 million term loan was secured from the Executive Chairman to support product development.

Pulse Biosciences (Nasdaq: PLSE) will report its third quarter 2022 financial results on November 10, 2022, after market close. A conference call will follow at 1:30pm PT / 4:30pm ET, where management will discuss the results. Investors can join the call by dialing 1-877-704-4453 (domestic) or 1-201-389-0920 (international), and a webcast will be available at investors.pulsebiosciences.com.

Pulse Biosciences (PLSE) has announced positive clinical results for its CellFX® System using Nano-Pulse Stimulation™ (NPS™) technology to treat low-risk basal cell carcinoma (BCC) lesions. An oral presentation at the 2022 American Society for Dermatologic Surgery Annual Meeting in Denver, from October 6-10, highlighted the technology's efficacy and favorable cosmetic outcomes. The study suggests NPS may provide a non-surgical and less scarring alternative to current treatment methods, potentially revolutionizing care for the 3.6 million U.S. patients affected by BCC annually.

Pulse Biosciences (Nasdaq: PLSE) announced that it has received FDA 510(k) clearance for its CellFX System, expanding treatment indications to include sebaceous hyperplasia for Fitzpatrick skin types I-III. This clearance is backed by clinical data from an IDE approved study. Additionally, the company introduced larger treatment tips (7.5mm and 10mm), enhancing the device's application for larger benign lesions. CEO Kevin Danahy expressed confidence in the system's effectiveness and potential market adoption.

Pulse Biosciences is focusing on advancing its core Nano-Pulse Stimulation (NPS) technology in the cardiac and oncology sectors while reducing its dermatology operations. Kevin Danahy has been appointed as the new CEO, with Darrin Uecker becoming Chief Technology Officer. The company has secured a $65 million loan from Robert Duggan, who now serves as Executive Chairman. Pulse aims to refine its strategic focus and expects to announce further progress in its healthcare initiatives within 60 days.

Pulse Biosciences, Inc. (Nasdaq: PLSE) reported Q2 2022 revenue of $265,000, a decrease from previous quarters, with notable activities including FDA clearance for expanded energy settings of the CellFX System. The company successfully completed two sales of the system and transitioned four clinics to commercial use, with 43 total conversions. Operating expenses saw a 23% reduction, totaling $14.3 million. The net loss was ($14.0 million) for the quarter. Cash reserves fell to $14.8 million from $47.4 million the previous year, signaling financial challenges.

Pulse Biosciences, Inc. (NASDAQ: PLSE) has received FDA 510(k) clearance for expanded energy settings for its CellFX System in dermatology. This allows U.S. clinicians to offer more customized treatment options for benign lesions. The FDA's expedited review took only 53 days, confirming the new settings' safety and efficacy. The CellFX System, powered by Nano-Pulse Stimulation technology, aims to improve dermatologic outcomes and deliver value through a utilization-based revenue model. The company remains committed to advancing its technology and expanding clinical applications.

Pulse Biosciences, Inc. (Nasdaq: PLSE) will release its second quarter 2022 financial results after market close on August 10, 2022. A conference call will follow at 1:30pm PT for investors to discuss the results. The company focuses on bioelectric medicine, offering the CellFX® System, which utilizes Nano-Pulse Stimulation™ technology for treating dermatologic conditions.